Treat-to-Target of Endoscopic Remission in Patients with IBD in Symptomatic Remission: The QUOTIENT Trial
-
Enrollment
This study is currently enrolling. -
Associated Conditions
-
Research Area
Digestive Health and Surgery -
Location
-
Principal Investigator
Jennifer Seminerio-Diehl -
Sponsor
Mayo Clinic Arizona
The purpose of this study is to collect and analyze data in patients with IBD who are currently receiving IBD medication(s) that targets their immune system (targeted immunomodulator [TIM]) in routine clinical care and to determine if switching to an alternative IBD medication will improve their disease outcome without increasing the burden of their treatment.
Enrollment Form
This study is currently enrolling.